Search

Your search keyword '"Gjertsen, Bjorn T."' showing total 230 results
Start Over Author "Gjertsen, Bjorn T."
230 results on '"Gjertsen, Bjorn T."'

3. Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects

Author

Geelen, Inge G.P., Gullaksen, Stein-Erik, Ilander, Mette M., Olssen-Strömberg, Ulla, Mustjoki, Satu, Richter, Johan, Blijlevens, Nicole M.A., Smit, Willem M., Gjertsen, Bjorn T., Gedde-Dahl, Tobias, Markevärn, Berit, Koppes, Malika M.A., Westerweel, Peter E., Hjorth-Hansen, Henrik, and Janssen, Jeroen J.W.M.

Published
2023
Full Text
View/download PDF

5. Overlapping features of therapy-related and de novo NPM1-mutated AML

Author

Othman, Jad, Meggendorfer, Manja, Tiacci, Enrico, Thiede, Christian, Schlenk, Richard, Dillon, Richard, Stasik, Sebastian, Venanzi, Alessandra, Bertoli, Sarah, Delabesse, Eric, Dumas, Pierre-Yves, Pigneux, Arnaud, Bidet, Audrey, Gilkes, Amanda F., Thomas, Ian, Voso, Maria Teresa, Rambaldi, Alessandro, Brunetti, Lorenzo, Perriello, Vincenzo M., Andresen, Vibeke, Gjertsen, Bjorn T., Martelli, Maria Paola, Récher, Christian, Röllig, Christoph, Bornhäuser, Martin, Serve, Hubert, Müller-Tidow, Carsten, Baldus, Claudia D., Haferlach, Tortsten, Russell, Nigel, and Falini, Brunangelo

Published
2023
Full Text
View/download PDF

6. Rapid label expansion based on public-private collaboration in IMPRESS-Norway.

Author

Helland, Aslaug, primary, Tasken, Kjetil, additional, Blix, Egil Støre, additional, Lonning, Per Eystein, additional, Gjertsen, Bjorn T., additional, Hovland, Randi, additional, Randen, Ulla, additional, Gilje, Bjornar, additional, Kyte, Jon Amund, additional, Flobak, Åsmund, additional, Russnes, Hege, additional, Fagereng, Gro Live, additional, and Smeland, Sigbjørn, additional

Published
2024
Full Text
View/download PDF

7. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Author

Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, Gradowska, Patrycja, Biemond, Bart J., Spertini, Olivier, Vellenga, Edo, Griskevicius, Laimonas, Tick, Lidwine W., Jongen-Lavrencic, Mojca, van Marwijk Kooy, Marinus, Vekemans, Marie-Christiane, van der Velden, Walter J.F.M., Beverloo, Berna, Michaux, Lucienne, Graux, Carlos, Deeren, Dries, de Weerdt, Okke, van Esser, Joost W.J., Bargetzi, Mario, Klein, Saskia K., Gadisseur, Alain, Westerweel, Peter E., Veelken, Hendrik, Gregor, Michael, Silzle, Tobias, van Lammeren-Venema, Daniëlle, Moors, Ine, Breems, Dimitri A., Hoogendoorn, Mels, Legdeur, Marie-Cecile J.C., Fischer, Thomas, Kuball, Juergen, Cornelissen, Jan, Porkka, Kimmo, Juliusson, Gunnar, Meyer, Peter, Höglund, Martin, Gjertsen, Bjorn T., Janssen, Jeroen J.W.M., Huls, Gerwin, Passweg, Jakob, Cloos, Jacqueline, Valk, Peter J.M., van Elssen, Catharina H.M.J., Manz, Markus G., Floisand, Yngvar, and Ossenkoppele, Gert J.

Published
2021
Full Text
View/download PDF

8. IFN-[alpha] with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia

Author

Huuhtanen, Jani, Ilander, Mette, Yadav, Bhagwan, Dufva, Olli M.J., Lahteenmaki, Hanna, Kasanen, Tiina, Klievink, Jay, Olsson-Stromberg, Ulla, Stentoft, Jesper, Richter, Johan, Koskenvesa, Perttu, Hoglund, Martin, Soderlund, Stina, Dreimane, Arta, Porkka, Kimmo, Gedde-Dahl, Tobias, Gjertsen, Bjorn T., Stenke, Leif, Myhr-Eriksson, Kristina, Markevarn, Berit, Lubking, Anna, Dimitrijevic, Andreja, Udby, Lene, Bjerrum, Ole Weis, Hjorth-Hansen, Henrik, and Mustjoki, Satu

Subjects
Immune system -- Health aspects, Interferon alpha -- Dosage and administration -- Physiological aspects, Dasatinib -- Dosage and administration -- Physiological aspects, Chronic myeloid leukemia -- Drug therapy -- Physiological aspects, Chemotherapy, Combination -- Methods -- Physiological aspects, Health care industry
Abstract

In chronic myeloid leukemia (CML), combination therapies with tyrosine kinase inhibitors (TKIs) aim to improve the achievement of deep molecular remission that would allow therapy discontinuation. IFN-[alpha] is one promising candidate, as it has long-lasting effects on both malignant and immune cells. In connection with a multicenter clinical trial combining dasatinib with IFN-[alpha] in 40 patients with chronic-phase CML (NordCML007, NCT01725204), we performed immune monitoring with single-cell RNA and T cell receptor (TCR) sequencing (n = 4, 12 samples), bulk TCR[beta] sequencing (n = 13, 26 samples), flow cytometry (n = 40, 106 samples), cytokine analyses (n = 17, 80 samples), and ex vivo functional studies (n = 39, 80 samples). Dasatinib drove the immune repertoire toward terminally differentiated NK and [CD8.sup.+] T cells with dampened functional capabilities. Patients with dasatinib-associated pleural effusions had increased numbers of [CD8.sup.+] recently activated effector memory T (Temra) cells. In vitro, dasatinib prevented CD3-induced cell death by blocking TCR signaling. The addition of IFN-[alpha] reversed the terminally differentiated phenotypes and increased the number of costimulatory intercellular interactions and the number of unique putative epitope-specific TCR clusters. In vitro IFN-[alpha] had costimulatory effects on TCR signaling. Our work supports the combination of IFN-[alpha] with TKI therapy, as IFN-[alpha] broadens the immune repertoire and restores immunological function., Introduction Currently, the ultimate therapeutic goal in patients with chronic-phase chronic myeloid leukemia (CP-CML) is to achieve deep molecular remission, which would allow the discontinuation of tyrosine kinase inhibitor (TKI) [...]

Published
2022
Full Text
View/download PDF

9. Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML

Author

Tettero, Jesse M., primary, Buisman, Yara, additional, Ngai, Lok Lam, additional, Bachas, Costa, additional, Gjertsen, Bjorn T., additional, Kelder, Angèle, additional, van de Loosdrecht, Arjan A., additional, Manz, Markus G., additional, Pabst, Thomas, additional, Scholten, Willemijn, additional, Ossenkoppele, Gert J., additional, Cloos, Jacqueline, additional, and de Leeuw, David C., additional

Published
2023
Full Text
View/download PDF

10. Prospective validation of the prognostic relevance of CD34+CD38– AML stem cell frequency in the HOVON-SAKK132 trial

Author

Ngai, Lok Lam, Hanekamp, Diana, Janssen, Fleur, Carbaat-Ham, Jannemieke, Hofland, Maaike A M, Fayed, Mona M H E, Kelder, Angèle, Oudshoorn-van Marsbergen, Laura, Scholten, Willemijn J, Snel, Alexander N, Bachas, Costa, Tettero, Jesse M, Breems, Dimitri A, Fischer, Thomas, Gjertsen, Bjorn T, Griskevicius, Laimonas, Juliusson, Gunnar, van de Loosdrecht, Arjan A, Maertens, Johan A, Manz, Markus G, Pabst, Thomas, Passweg, Jakob R, Porkka, Kimmo, Valk, Peter J M, Gradowska, Patrycja, Löwenberg, Bob, de Leeuw, David C, Janssen, Jeroen J W M, Ossenkoppele, Gert J, Cloos, Jacqueline, Hematology laboratory, VU University medical center, Hematology, AII - Cancer immunology, AII - Inflammatory diseases, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, and CCA - Cancer Treatment and quality of life

Subjects
All institutes and research themes of the Radboud University Medical Center, Immunology, Cell Biology, Hematology, 610 Medicine & health, Biochemistry, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
Abstract

Item does not contain fulltext

Published
2023

11. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML

Author

Karjalainen, Riikka, Pemovska, Tea, Popa, Mihaela, Liu, Minxia, Javarappa, Komal K., Majumder, Muntasir M., Yadav, Bhagwan, Tamborero, David, Tang, Jing, Bychkov, Dmitrii, Kontro, Mika, Parsons, Alun, Suvela, Minna, Mayoral Safont, Mireia, Porkka, Kimmo, Aittokallio, Tero, Kallioniemi, Olli, McCormack, Emmet, Gjertsen, Bjørn T., Wennerberg, Krister, Knowles, Jonathan, and Heckman, Caroline A.

Published
2017
Full Text
View/download PDF

12. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML

Author

Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, van Norden, Yvette, Biemond, Bart J., Schouten, Harry C., Spertini, Olivier, Vellenga, Edo, Graux, Carlos, Havelange, Violaine, de Greef, Georgine E., de Weerdt, Okke, Legdeur, Marie-Cecile J.C., Kuball, Juergen, Kooy, Marinus van Marwijk, Gjertsen, Bjorn T., Jongen-Lavrencic, Mojca, van de Loosdrecht, Arjan A., van Lammeren-Venema, Daniëlle, Hodossy, Beata, Breems, Dimitri A., Chalandon, Yves, Passweg, Jakob, Valk, Peter J.M., Manz, Markus G., and Ossenkoppele, Gert J.

Published
2017
Full Text
View/download PDF

14. Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival

Author

Tettero, Jesse M., primary, Ngai, Lok Lam, additional, Bachas, Costa, additional, Breems, Dimitri A., additional, Fischer, Thomas, additional, Gjertsen, Bjorn T., additional, Gradowska, Patrycja, additional, Griskevicius, Laimonas, additional, Janssen, Jeroen J.W.M., additional, Juliusson, Gunnar, additional, Maertens, Johan, additional, Manz, Markus G., additional, Pabst, Thomas, additional, Passweg, Jakob, additional, Porkka, Kimmo, additional, Valk, Peter J.M., additional, Löwenberg, Bob, additional, Ossenkoppele, Gert J., additional, and Cloos, Jacqueline, additional

Published
2023
Full Text
View/download PDF

15. Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival

Author

Tettero, Jesse M., Ngai, Lok Lam, Bachas, Costa, Breems, Dimitri A., Fischer, Thomas, Gjertsen, Bjorn T., Gradowska, Patrycja, Griskevicius, Laimonas, Janssen, Jeroen J.W.M., Juliusson, Gunnar, Maertens, Johan, Manz, Markus G., Pabst, Thomas, Passweg, Jakob, Porkka, Kimmo, Valk, Peter J.M., Löwenberg, Bob, Ossenkoppele, Gert J., Cloos, Jacqueline, Tettero, Jesse M., Ngai, Lok Lam, Bachas, Costa, Breems, Dimitri A., Fischer, Thomas, Gjertsen, Bjorn T., Gradowska, Patrycja, Griskevicius, Laimonas, Janssen, Jeroen J.W.M., Juliusson, Gunnar, Maertens, Johan, Manz, Markus G., Pabst, Thomas, Passweg, Jakob, Porkka, Kimmo, Valk, Peter J.M., Löwenberg, Bob, Ossenkoppele, Gert J., and Cloos, Jacqueline

Published
2023

16. Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML

Author

Tettero, Jesse M; https://orcid.org/0000-0002-0811-0824, Buisman, Yara, Ngai, Lok Lam; https://orcid.org/0000-0003-0969-3766, Bachas, Costa; https://orcid.org/0000-0001-5983-6193, Gjertsen, Bjorn T; https://orcid.org/0000-0001-9358-9704, Kelder, Angèle, van de Loosdrecht, Arjan A; https://orcid.org/0000-0001-8311-983X, Manz, Markus G; https://orcid.org/0000-0002-4676-7931, Pabst, Thomas; https://orcid.org/0000-0002-6055-5257, Scholten, Willemijn, Ossenkoppele, Gert J, Cloos, Jacqueline; https://orcid.org/0000-0001-9150-8026, de Leeuw, David C; https://orcid.org/0000-0003-4591-8467, Tettero, Jesse M; https://orcid.org/0000-0002-0811-0824, Buisman, Yara, Ngai, Lok Lam; https://orcid.org/0000-0003-0969-3766, Bachas, Costa; https://orcid.org/0000-0001-5983-6193, Gjertsen, Bjorn T; https://orcid.org/0000-0001-9358-9704, Kelder, Angèle, van de Loosdrecht, Arjan A; https://orcid.org/0000-0001-8311-983X, Manz, Markus G; https://orcid.org/0000-0002-4676-7931, Pabst, Thomas; https://orcid.org/0000-0002-6055-5257, Scholten, Willemijn, Ossenkoppele, Gert J, Cloos, Jacqueline; https://orcid.org/0000-0001-9150-8026, and de Leeuw, David C; https://orcid.org/0000-0003-4591-8467

Published
2023

17. Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival

Author

Tettero, Jesse M, Ngai, Lok Lam, Bachas, Costa, Breems, Dimitri A, Fischer, Thomas, Gjertsen, Bjorn T, Gradowska, Patrycja, Griskevicius, Laimonas, Janssen, Jeroen J W M, Juliusson, Gunnar, Maertens, Johan, Manz, Markus G; https://orcid.org/0000-0002-4676-7931, Pabst, Thomas, Passweg, Jakob, Porkka, Kimmo, Valk, Peter J M; https://orcid.org/0000-0002-8857-9461, Löwenberg, Bob; https://orcid.org/0000-0001-8982-5217, Ossenkoppele, Gert J, Cloos, Jacqueline, Tettero, Jesse M, Ngai, Lok Lam, Bachas, Costa, Breems, Dimitri A, Fischer, Thomas, Gjertsen, Bjorn T, Gradowska, Patrycja, Griskevicius, Laimonas, Janssen, Jeroen J W M, Juliusson, Gunnar, Maertens, Johan, Manz, Markus G; https://orcid.org/0000-0002-4676-7931, Pabst, Thomas, Passweg, Jakob, Porkka, Kimmo, Valk, Peter J M; https://orcid.org/0000-0002-8857-9461, Löwenberg, Bob; https://orcid.org/0000-0001-8982-5217, Ossenkoppele, Gert J, and Cloos, Jacqueline

Published
2023

20. Use of an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML-Patients Results in MRD Conversion, Improved Relapse-Free Survival and Vaccine Induced Immune Responses to Tumor Antigens

Author

Van de Loosdrecht, Arjan A., primary, Cloos, Jacqueline, additional, Wagner-Drouet, Eva-Maria, additional, Platzbecker, Uwe, additional, Holderried, Tobias A.W., additional, van Elssen, Catharina, additional, Giagounidis, Aristoteles, additional, Lehmann, Sören, additional, van Zeeburg, Hester J.T., additional, Rovers, Jeroen, additional, and Gjertsen, Bjorn T., additional

Published
2022
Full Text
View/download PDF

21. Induction of a Systemic Immune Response during Use of an Allogenic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML Patients Correlates with Clinical Response and MRD Conversion

Author

Van de Loosdrecht, Arjan A., primary, Cloos, Jacqueline, additional, Wagner-Drouet, Eva-Maria, additional, Platzbecker, Uwe, additional, Holderried, Tobias A.W., additional, van Elssen, Catharina, additional, Giagounidis, Aristoteles, additional, Welters, Marij J.P., additional, van der Burg, Sjoerd H., additional, van Zeeburg, Hester J.T., additional, Rovers, Jeroen, additional, and Gjertsen, Bjorn T., additional

Published
2022
Full Text
View/download PDF

22. Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis

Author

Tettero, Jesse M., primary, Al-Badri, Waleed K. W., additional, Ngai, Lok Lam, additional, Bachas, Costa, additional, Breems, Dimitri A., additional, van Elssen, Catharina H. M. J., additional, Fischer, Thomas, additional, Gjertsen, Bjorn T., additional, van Gorkom, Gwendolyn N. Y., additional, Gradowska, Patrycja, additional, Greuter, Marjolein J. E., additional, Griskevicius, Laimonas, additional, Juliusson, Gunnar, additional, Maertens, Johan, additional, Manz, Markus G., additional, Pabst, Thomas, additional, Passweg, Jakob, additional, Porkka, Kimmo, additional, Löwenberg, Bob, additional, Ossenkoppele, Gert J., additional, Janssen, Jeroen J. W. M., additional, and Cloos, Jacqueline, additional

Published
2022
Full Text
View/download PDF

23. The added value of multi-state modelling in a randomized controlled trial:The HOVON 102 study re-analyzed

Author

Bakunina, Katerina, Putter, Hein, Versluis, Jurjen, Koster, Eva A.S., van der Holt, Bronno, Manz, Markus G., Breems, Dimitri A., Gjertsen, Bjorn T., Cloos, Jacqueline, Valk, Peter J.M., Passweg, Jakob, Pabst, Thomas, Ossenkoppele, Gert J., Löwenberg, Bob, Cornelissen, Jan J., de Wreede, Liesbeth C., Bakunina, Katerina, Putter, Hein, Versluis, Jurjen, Koster, Eva A.S., van der Holt, Bronno, Manz, Markus G., Breems, Dimitri A., Gjertsen, Bjorn T., Cloos, Jacqueline, Valk, Peter J.M., Passweg, Jakob, Pabst, Thomas, Ossenkoppele, Gert J., Löwenberg, Bob, Cornelissen, Jan J., and de Wreede, Liesbeth C.

Abstract

Clofarabine is an active antileukemic drug for subgroups of patients with acute myeloid leukemia (AML). Multi-state models can provide additional insights to supplement the original intention-to-treat analysis of randomized controlled trials (RCT). We re-analyzed the HOVON102/SAKK30/09 phase III RCT for newly diagnosed AML patients, which randomized between standard induction chemotherapy with or without clofarabine. Using multi-state models, we evaluated the effects of induction chemotherapy outcomes (complete remission [CR], measurable residual disease [MRD]), and post-remission therapy with allogeneic stem cell transplantation [alloSCT] on relapse and death. Through the latter a consistent reduction in the hazard of relapse in the clofarabine arm compared to the standard arm was found, which occurred irrespective of MRD status or post-remission treatment with alloSCT, demonstrating a strong and persistent antileukemic effect of clofarabine. During the time period between achieving CR and possible post-remission treatment with alloSCT, non-relapse mortality was higher in patients receiving clofarabine. An overall net benefit of treatment with clofarabine was identified using the composite endpoint current leukemia-free survival (CLFS). In conclusion, these results enforce and extend the earlier reported beneficial effect of clofarabine in AML and show that multi-state models further detail the effect of treatment on competing and series of events.

Published
2022

24. Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia:An outcome- and cost-analysis

Author

Tettero, Jesse M., Al-Badri, Waleed K.W., Ngai, Lok Lam, Bachas, Costa, Breems, Dimitri A., van Elssen, Catharina H.M.J., Fischer, Thomas, Gjertsen, Bjorn T., van Gorkom, Gwendolyn N.Y., Gradowska, Patrycja, Greuter, Marjolein J.E., Griskevicius, Laimonas, Juliusson, Gunnar, Maertens, Johan, Manz, Markus G., Pabst, Thomas, Passweg, Jakob, Porkka, Kimmo, Löwenberg, Bob, Ossenkoppele, Gert J., Janssen, Jeroen J.W.M., Cloos, Jacqueline, Tettero, Jesse M., Al-Badri, Waleed K.W., Ngai, Lok Lam, Bachas, Costa, Breems, Dimitri A., van Elssen, Catharina H.M.J., Fischer, Thomas, Gjertsen, Bjorn T., van Gorkom, Gwendolyn N.Y., Gradowska, Patrycja, Greuter, Marjolein J.E., Griskevicius, Laimonas, Juliusson, Gunnar, Maertens, Johan, Manz, Markus G., Pabst, Thomas, Passweg, Jakob, Porkka, Kimmo, Löwenberg, Bob, Ossenkoppele, Gert J., Janssen, Jeroen J.W.M., and Cloos, Jacqueline

Abstract

Measurable residual disease (MRD) measured using multiparameter flow-cytometry (MFC) has proven to be an important prognostic biomarker in acute myeloid leukemia (AML). In addition, MRD is increasingly used to guide consolidation treatment towards a non-allogenic stem cell transplantation treatment for MRD-negative patients in the ELN-2017 intermediate risk group. Currently, measurement of MFC-MRD in bone marrow is used for clinical decision making after 2 cycles of induction chemotherapy. However, measurement after 1 cycle has also been shown to have prognostic value, so the optimal time point remains a question of debate. We assessed the independent prognostic value of MRD results at either time point and concordance between these for 273 AML patients treated within and according to the HOVON-SAKK 92, 102, 103 and 132 trials. Cumulative incidence of relapse, event free survival and overall survival were significantly better for MRD-negative (<0.1%) patients compared to MRD-positive patients after cycle 1 and cycle 2 (p ≤ 0.002, for all comparisons). A total of 196 patients (71.8%) were MRD-negative after cycle 1, of which the vast majority remained negative after cycle 2 (180 patients; 91.8%). In contrast, of the 77 MRD-positive patients after cycle 1, only 41 patients (53.2%) remained positive. A cost reduction of –€571,751 per 100 patients could be achieved by initiating the donor search based on the MRD-result after cycle 1. This equals to a 50.7% cost reduction compared to the current care strategy in which the donor search is initiated for all patients. These results show that MRD after cycle 1 has prognostic value and is highly concordant with MRD status after cycle 2. When MRD-MFC is used to guide consolidation treatment (allo vs non-allo) in intermediate risk patients, allogeneic donor search may be postponed or omitted after cycle 1. Since the majority of MRD-negative patients remain negative after cycle 2, this could safely reduce the number of all

Published
2022

25. Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis

Author

Tettero, Jesse M, Al-Badri, Waleed K W, Ngai, Lok Lam, Bachas, Costa, Breems, Dimitri A, van Elssen, Catharina H M J, Fischer, Thomas, Gjertsen, Bjorn T, van Gorkom, Gwendolyn N Y, Gradowska, Patrycja, Greuter, Marjolein J E, Griskevicius, Laimonas, Juliusson, Gunnar, Maertens, Johan, Manz, Markus G; https://orcid.org/0000-0002-4676-7931, Pabst, Thomas, Passweg, Jakob, Porkka, Kimmo, Löwenberg, Bob, Ossenkoppele, Gert J, Janssen, Jeroen J W M, Cloos, Jacqueline, Tettero, Jesse M, Al-Badri, Waleed K W, Ngai, Lok Lam, Bachas, Costa, Breems, Dimitri A, van Elssen, Catharina H M J, Fischer, Thomas, Gjertsen, Bjorn T, van Gorkom, Gwendolyn N Y, Gradowska, Patrycja, Greuter, Marjolein J E, Griskevicius, Laimonas, Juliusson, Gunnar, Maertens, Johan, Manz, Markus G; https://orcid.org/0000-0002-4676-7931, Pabst, Thomas, Passweg, Jakob, Porkka, Kimmo, Löwenberg, Bob, Ossenkoppele, Gert J, Janssen, Jeroen J W M, and Cloos, Jacqueline

Abstract

Measurable residual disease (MRD) measured using multiparameter flow-cytometry (MFC) has proven to be an important prognostic biomarker in acute myeloid leukemia (AML). In addition, MRD is increasingly used to guide consolidation treatment towards a non-allogenic stem cell transplantation treatment for MRD-negative patients in the ELN-2017 intermediate risk group. Currently, measurement of MFC-MRD in bone marrow is used for clinical decision making after 2 cycles of induction chemotherapy. However, measurement after 1 cycle has also been shown to have prognostic value, so the optimal time point remains a question of debate. We assessed the independent prognostic value of MRD results at either time point and concordance between these for 273 AML patients treated within and according to the HOVON-SAKK 92, 102, 103 and 132 trials. Cumulative incidence of relapse, event free survival and overall survival were significantly better for MRD-negative (<0.1%) patients compared to MRD-positive patients after cycle 1 and cycle 2 (p ≤ 0.002, for all comparisons). A total of 196 patients (71.8%) were MRD-negative after cycle 1, of which the vast majority remained negative after cycle 2 (180 patients; 91.8%). In contrast, of the 77 MRD-positive patients after cycle 1, only 41 patients (53.2%) remained positive. A cost reduction of -€571,751 per 100 patients could be achieved by initiating the donor search based on the MRD-result after cycle 1. This equals to a 50.7% cost reduction compared to the current care strategy in which the donor search is initiated for all patients. These results show that MRD after cycle 1 has prognostic value and is highly concordant with MRD status after cycle 2. When MRD-MFC is used to guide consolidation treatment (allo vs non-allo) in intermediate risk patients, allogeneic donor search may be postponed or omitted after cycle 1. Since the majority of MRD-negative patients remain negative after cycle 2, this could safely reduce the number of allogenei

Published
2022

26. The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzed

Author

Bakunina, Katerina; https://orcid.org/0000-0003-3737-7971, Putter, Hein, Versluis, Jurjen, Koster, Eva A S; https://orcid.org/0000-0002-8446-5133, van der Holt, Bronno, Manz, Markus G, Breems, Dimitri A, Gjertsen, Bjorn T, Cloos, Jacqueline, Valk, Peter J M, Passweg, Jakob, Pabst, Thomas, Ossenkoppele, Gert J, Löwenberg, Bob, Cornelissen, Jan J, de Wreede, Liesbeth C, Bakunina, Katerina; https://orcid.org/0000-0003-3737-7971, Putter, Hein, Versluis, Jurjen, Koster, Eva A S; https://orcid.org/0000-0002-8446-5133, van der Holt, Bronno, Manz, Markus G, Breems, Dimitri A, Gjertsen, Bjorn T, Cloos, Jacqueline, Valk, Peter J M, Passweg, Jakob, Pabst, Thomas, Ossenkoppele, Gert J, Löwenberg, Bob, Cornelissen, Jan J, and de Wreede, Liesbeth C

Abstract

Clofarabine is an active antileukemic drug for subgroups of patients with acute myeloid leukemia (AML). Multi-state models can provide additional insights to supplement the original intention-to-treat analysis of randomized controlled trials (RCT). We re-analyzed the HOVON102/SAKK30/09 phase III RCT for newly diagnosed AML patients, which randomized between standard induction chemotherapy with or without clofarabine. Using multi-state models, we evaluated the effects of induction chemotherapy outcomes (complete remission [CR], measurable residual disease [MRD]), and post-remission therapy with allogeneic stem cell transplantation [alloSCT] on relapse and death. Through the latter a consistent reduction in the hazard of relapse in the clofarabine arm compared to the standard arm was found, which occurred irrespective of MRD status or post-remission treatment with alloSCT, demonstrating a strong and persistent antileukemic effect of clofarabine. During the time period between achieving CR and possible post-remission treatment with alloSCT, non-relapse mortality was higher in patients receiving clofarabine. An overall net benefit of treatment with clofarabine was identified using the composite endpoint current leukemia-free survival (CLFS). In conclusion, these results enforce and extend the earlier reported beneficial effect of clofarabine in AML and show that multi-state models further detail the effect of treatment on competing and series of events.

Published
2022

28. The added value of multi‐state modelling in a randomized controlled trial: The HOVON 102 study re‐analyzed

Author

Bakunina, Katerina, primary, Putter, Hein, additional, Versluis, Jurjen, additional, Koster, Eva A. S., additional, van der Holt, Bronno, additional, Manz, Markus G., additional, Breems, Dimitri A., additional, Gjertsen, Bjorn T., additional, Cloos, Jacqueline, additional, Valk, Peter J. M., additional, Passweg, Jakob, additional, Pabst, Thomas, additional, Ossenkoppele, Gert J., additional, Löwenberg, Bob, additional, Cornelissen, Jan J., additional, and de Wreede, Liesbeth C., additional

Published
2021
Full Text
View/download PDF

29. Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in AML Patients Shows MRD Conversion and Improved Survival

Author

Van de Loosdrecht, Arjan A., primary, Cloos, Jacqueline, additional, Wagner, Eva Maria, additional, Platzbecker, Uwe, additional, Holderried, Tobias A. W., additional, van Elssen, Janine, additional, Giagounidis, Aristoteles, additional, Lehmann, Soren, additional, van Zeeburg, Hester, additional, Rovers, Jeroen, additional, and Gjertsen, Bjorn T., additional

Published
2021
Full Text
View/download PDF

30. Bemcentinib (Oral AXL Inhibitor) in Combination with Low-Dose Cytarabine Is Well Tolerated and Efficacious in Older Relapsed AML Patients.Updates from the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results Indicating Bemcentinib Elicits Anti-AML Immune Responses

Author

Loges, Sonja, primary, Sutamtewagul, Grerk, additional, Heuser, Michael, additional, Chromik, Jörg, additional, Kapp-Schwoerer, Silke, additional, Crugnola, Monica, additional, Di Renzo, Nicola, additional, Lemoli, Roberto M., additional, Mattei, Daniele Giovanni, additional, Ben Batalla, Isabel, additional, Hellesøy, Monica, additional, Waizenegger, Jonas, additional, Janning, Melanie, additional, Imbusch, Charles D., additional, Beumer, Niklas, additional, Rayford, Austin, additional, Nautiyal, Jaya, additional, Berkman-Gottlieb, Tzivia, additional, Micklem, David, additional, Gabra, Hani, additional, Gorcea-Carson, Claudia, additional, Lorens, James B., additional, Fiedler, Walter, additional, Alvarado, Yesid, additional, Gjertsen, Bjorn T., additional, and Rieckmann, Lisa-Marie, additional

Published
2021
Full Text
View/download PDF

32. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (MGD) Service d'hématologie, UCL - (SLuc) Service d'hématologie, Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, Gradowska, Patrycja, Biemond, Bart J, Spertini, Olivier, Vellenga, Edo, Griskevicius, Laimonas, Tick, Lidwine W, Jongen-Lavrencic, Mojca, van Marwijk Kooy, Marinus, Vekemans, Marie-Christiane, van der Velden, Walter J F M, Beverloo, Berna, Michaux, Lucienne, Graux, Carlos, Deeren, Dries, de Weerdt, Okke, van Esser, Joost W J, Bargetzi, Mario, Klein, Saskia K, Gadisseur, Alain, Westerweel, Peter E, Veelken, Hendrik, Gregor, Michael, Silzle, Tobias, van Lammeren-Venema, Daniëlle, Moors, Ine, Breems, Dimitri A, Hoogendoorn, Mels, Legdeur, Marie-Cecile J C, Fischer, Thomas, Kuball, Juergen, Cornelissen, Jan, Porkka, Kimmo, Juliusson, Gunnar, Meyer, Peter, Höglund, Martin, Gjertsen, Bjorn T, Janssen, Jeroen J W M, Huls, Gerwin, Passweg, Jakob, Cloos, Jacqueline, Valk, Peter J M, van Elssen, Catharina H M J, Manz, Markus G, Floisand, Yngvar, Ossenkoppele, Gert J, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (MGD) Service d'hématologie, UCL - (SLuc) Service d'hématologie, Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, Gradowska, Patrycja, Biemond, Bart J, Spertini, Olivier, Vellenga, Edo, Griskevicius, Laimonas, Tick, Lidwine W, Jongen-Lavrencic, Mojca, van Marwijk Kooy, Marinus, Vekemans, Marie-Christiane, van der Velden, Walter J F M, Beverloo, Berna, Michaux, Lucienne, Graux, Carlos, Deeren, Dries, de Weerdt, Okke, van Esser, Joost W J, Bargetzi, Mario, Klein, Saskia K, Gadisseur, Alain, Westerweel, Peter E, Veelken, Hendrik, Gregor, Michael, Silzle, Tobias, van Lammeren-Venema, Daniëlle, Moors, Ine, Breems, Dimitri A, Hoogendoorn, Mels, Legdeur, Marie-Cecile J C, Fischer, Thomas, Kuball, Juergen, Cornelissen, Jan, Porkka, Kimmo, Juliusson, Gunnar, Meyer, Peter, Höglund, Martin, Gjertsen, Bjorn T, Janssen, Jeroen J W M, Huls, Gerwin, Passweg, Jakob, Cloos, Jacqueline, Valk, Peter J M, van Elssen, Catharina H M J, Manz, Markus G, Floisand, Yngvar, and Ossenkoppele, Gert J

Abstract

Lenalidomide, an antineoplastic and immunomodulatory drug, has therapeutic activity in acute myeloid leukemia (AML), but definitive studies about its therapeutic utility have been lacking. In a phase 3 study, we compared 2 induction regimens in newly diagnosed patients age 18 to 65 years with AML: idarubicine-cytarabine (cycle 1) and daunorubicin and intermediate-dose cytarabine (cycle 2) without or with lenalidomide (15 mg orally on days 1-21). One final consolidation cycle of chemotherapy or autologous stem cell transplantation (auto-SCT) or allogeneic SCT (allo-SCT) was provided according to a prognostic risk and minimal residual disease (MRD)-adapted approach. Event-free survival (EFS; primary end point) and other clinical end points were assessed. A second random assignment in patients in complete response or in complete response with incomplete hematologic recovery after cycle 3 or auto-SCT involved 6 cycles of maintenance with lenalidomide (10 mg on days 1-21) or observation. In all, 392 patients were randomly assigned to the control group, and 388 patients were randomly assigned to lenalidomide induction. At a median follow-up of 41 months, the study revealed no differences in outcome between the treatments (EFS, 44% ± 2% standard error and overall survival, 54% ± 2% at 4 years for both arms) although in an exploratory post hoc analysis, a lenalidomide benefit was suggested in SRSF2-mutant AML. In relation to the previous Dutch-Belgian Hemato-Oncology Cooperative Group and Swiss Group for Clinical Cancer Research (HOVON-SAKK) studies that used a similar 3-cycle regimen but did not pursue an MRD-guided approach, these survival estimates compare markedly more favorably. MRD status after cycle 2 lost prognostic value in intermediate-risk AML in the risk-adjusted treatment context. Maintenance with lenalidomide showed no apparent effect on relapse probability in 88 patients randomly assigned for this part of the study.

Published
2021

33. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Author

CTI Kuball, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, Gradowska, Patrycja, Biemond, Bart J, Spertini, Olivier, Vellenga, Edo, Griskevicius, Laimonas, Tick, Lidwine W, Jongen-Lavrencic, Mojca, van Marwijk Kooy, Marinus, Vekemans, Marie-Christiane, van der Velden, Walter J F M, Beverloo, Berna, Michaux, Lucienne, Graux, Carlos, Deeren, Dries, de Weerdt, Okke, van Esser, Joost W J, Bargetzi, Mario, Klein, Saskia K, Gadisseur, Alain, Westerweel, Peter E, Veelken, Hendrik, Gregor, Michael, Silzle, Tobias, van Lammeren-Venema, Daniëlle, Moors, Ine, Breems, Dimitri A, Hoogendoorn, Mels, Legdeur, Marie-Cecile J C, Fischer, Thomas, Kuball, Juergen, Cornelissen, Jan, Porkka, Kimmo, Juliusson, Gunnar, Meyer, Peter, Höglund, Martin, Gjertsen, Bjorn T, Janssen, Jeroen J W M, Huls, Gerwin, Passweg, Jakob, Cloos, Jacqueline, Valk, Peter J M, van Elssen, Catharina H M J, Manz, Markus G, Floisand, Yngvar, Ossenkoppele, Gert J, CTI Kuball, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, Gradowska, Patrycja, Biemond, Bart J, Spertini, Olivier, Vellenga, Edo, Griskevicius, Laimonas, Tick, Lidwine W, Jongen-Lavrencic, Mojca, van Marwijk Kooy, Marinus, Vekemans, Marie-Christiane, van der Velden, Walter J F M, Beverloo, Berna, Michaux, Lucienne, Graux, Carlos, Deeren, Dries, de Weerdt, Okke, van Esser, Joost W J, Bargetzi, Mario, Klein, Saskia K, Gadisseur, Alain, Westerweel, Peter E, Veelken, Hendrik, Gregor, Michael, Silzle, Tobias, van Lammeren-Venema, Daniëlle, Moors, Ine, Breems, Dimitri A, Hoogendoorn, Mels, Legdeur, Marie-Cecile J C, Fischer, Thomas, Kuball, Juergen, Cornelissen, Jan, Porkka, Kimmo, Juliusson, Gunnar, Meyer, Peter, Höglund, Martin, Gjertsen, Bjorn T, Janssen, Jeroen J W M, Huls, Gerwin, Passweg, Jakob, Cloos, Jacqueline, Valk, Peter J M, van Elssen, Catharina H M J, Manz, Markus G, Floisand, Yngvar, and Ossenkoppele, Gert J

Published
2021

35. The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia

Author

Ngai, Lok Lam, Hanekamp, Diana, Kelder, Angèle, Scholten, Willemijn, Carbaat-Ham, Jannemieke, Fayed, Mona M.H.E, Snel, Alexander N., Bachas, Costa, Tettero, Jesse M., Mocking, Tim R., Van Der Velden, Vincent H.J., Slomp, Jennichjen, Hobo, Willemijn, Breems, Dimitri, Fischer, Thomas, Gjertsen, Bjorn T., Griškevičius, Laimonas, Juliusson, Gunnar, Maertens, Johan, Manz, Markus G., Pabst, Thomas, Passweg, Jakob, Sr., Porkka, Kimmo, Valk, Peter J. M., Gradowska, Patrycja, Löwenberg, Bob, de Leeuw, David C., van de Loosdrecht, Arjan A., Ossenkoppele, Gert, and Cloos, Jacqueline

Published
2023
Full Text
View/download PDF

37. Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON-SAKK Studies

Author

Ngai, Lok Lam, Veenstra, Coen R., Gradowska, Patrycja, Kelder, Angèle, Scholten, Willemijn, Snel, Alexander N., Tettero, Jesse M., Bachas, Costa, Breems, Dimitri, Fischer, Thomas, Gjertsen, Bjorn T., Griškevičius, Laimonas, Juliusson, Gunnar, Maertens, Johan, Manz, Markus G., Pabst, Thomas, Passweg, Jakob, Sr., Porkka, Kimmo, Alhan, Canan, Westers, Theresia M., Valk, Peter J. M., de Leeuw, David C., Lowenberg, Bob, Ossenkoppele, Gert, Cloos, Jacqueline, and van de Loosdrecht, Arjan A.

Published
2023
Full Text
View/download PDF

38. Phase Ib/II Study (NCT02488408 / BGBC003) of Bemcentinib Monotherapy or in Combination with Cytarabine or Decitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): FINAL Results

Author

Loges, Sonja, Heuser, Michael, Chromik, Jolanta, Sutamtewagul, Grerk, Kapp-Schwoerer, Silke, Crugnola, Monica, Di Renzo, Nicola, Lemoli, Roberto Massimo, Mattei, Daniele Giovanni, Ben Batalla, Isabel, Waizenegger, Jonas, Janning, Melanie, Rieckmann, Lisa-Marie, Imbusch, Charles, Beumer, Niklas, Micklam, David, Gorcea-Carson, Claudia, Oliva, Cristina, Fiedler, Walter, Alvarado-Valero, Yesid, McCracken, Nigel, and Gjertsen, Bjorn T.

Published
2023
Full Text
View/download PDF

41. Multi-parametric single cell evaluation defines distinct drug responses in healthy hematological cells that are retained in corresponding malignant cell types.

Author

Majumder, Muntasir M, Leppa, Aino-Maija, Hellesoy, Monica, Dowling, Paul, Malyutina, Alina, Kopperud, Reidun, Bazou, Despina, Andersson, Emma, Parsons, Alun, Tang, Jing, Kallioniemi, Olli, Mustjoki, Satu, O'Gorman, Peter, Wennerberg, Krister, Porkka, Kimmo, Gjertsen, Bjorn T, Heckman, Caroline A, Majumder, Muntasir M, Leppa, Aino-Maija, Hellesoy, Monica, Dowling, Paul, Malyutina, Alina, Kopperud, Reidun, Bazou, Despina, Andersson, Emma, Parsons, Alun, Tang, Jing, Kallioniemi, Olli, Mustjoki, Satu, O'Gorman, Peter, Wennerberg, Krister, Porkka, Kimmo, Gjertsen, Bjorn T, and Heckman, Caroline A

Abstract

Innate drug sensitivity in healthy cells aids identification of lineage specific anti-cancer therapies and reveals off-target effects. To characterize the diversity in drug responses in the major hematopoietic cell types, we simultaneously assessed their sensitivity to 71 small molecules utilizing a multi-parametric flow cytometry assay and mapped their proteomic and basal signaling profiles. Unsupervised hierarchical clustering identified distinct drug responses in healthy cell subsets based on their cellular lineage. Compared to other cell types, CD19+ /B and CD56+ /NK cells were more sensitive to dexamethasone, venetoclax and midostaurin, while monocytes were more sensitive to trametinib. Venetoclax exhibited dose-dependent cell selectivity that inversely correlated to STAT3 phosphorylation. Lineage specific effect of midostaurin was similarly detected in CD19+ /B cells from healthy, acute myeloid leukemia and chronic lymphocytic leukemia samples. Comparison of drug responses in healthy and neoplastic cells showed that healthy cell responses are predictive of the corresponding malignant cell response. Taken together, understanding drug sensitivity in the healthy cell-of-origin provides opportunities to obtain a new level of therapy precision and avoid off-target toxicity.

Published
2020

43. Contributors

Author

Ackerman, Michael J., primary, Anderson, Matthew L., additional, Andreotti, Felicita, additional, Annex, Brian H., additional, Antonellis, Anthony, additional, Artemov, Dmitri, additional, Bain, James R., additional, Barnes, Peter J., additional, Barnholtz-Sloan, J.S., additional, Becker, Richard C., additional, Benjamin, Ivor J., additional, Billings, Paul R., additional, Body, Simon C., additional, Boguski, Mark, additional, Bonassi, Stefano, additional, Bondy, Brigitta, additional, Bos, J. Martijn, additional, Breitbart, Roger E., additional, Brody, Jerome, additional, Brown, Matthew P., additional, Bullinger, Lars, additional, Burgess, Shawn C., additional, Butte, Atul J., additional, Carey, David J., additional, Carlson, George, additional, Celedón, Juan C., additional, Chandrasekharan, Subhashini, additional, Chang, Wing C. (John), additional, Chen, Yan, additional, Chiocca, Antonio, additional, Chow, Theresa Puifun, additional, Chung, Wendy K., additional, Cook-Deegan, Robert, additional, Corella, Dolores, additional, Cottrell, Susan, additional, Cox, Nancy J., additional, Crawford, Nigel P.S., additional, Cuticchia, A. Jamie, additional, Deforce, Dieter, additional, Deng, Mario C., additional, Devi, Gayathri, additional, deVos, Theo, additional, Distler, Juergen, additional, Dohner, Harmut, additional, Dokun, Ayotunde O., additional, Edbrooke, Mark R., additional, Edelman, Lucas B., additional, Elewaut, Dirk, additional, Epstein, Charles J., additional, Fanous, Ayman H., additional, Febbo, Phillip G., additional, Feezor, Robert J., additional, Feng, Yonmei, additional, Földes-Papp, Zeno, additional, Fujinaka, Hidehiko, additional, Galas, David J., additional, Garrison, Louis, P., additional, Gerhard, Glenn S., additional, Ginsburg, Geoffrey S., additional, Gjertsen, Bjorn T., additional, Glass, Michael, additional, Goldstein, David B., additional, Gordon, Erynn S., additional, Gosnell, Tucker, additional, Grass, Peter, additional, Green, Eric D., additional, Grossman, Iris, additional, Gwinn, Marta, additional, Haefliger, Carolina, additional, Haga, Susanne B., additional, Hall, Per, additional, Hare, Joshua M., additional, Hariri, Ahmad, additional, Heath, James R., additional, Hegele, Robert A., additional, Heidecker, Bettina, additional, Hislop, Shona, additional, Hoffman, Eric P., additional, Holton, John, additional, Hood, Leroy, additional, Huang, Andrew T., additional, Huang, Erich S., additional, Hubbard, Carlos A., additional, Hunter, Kent, additional, Hyland, Courtney, additional, Ihm, Chunhwa, additional, Ilkayeva, Olga, additional, Irizarry, Rafael, additional, Jain, Shushant, additional, Johnson, Melissa D., additional, Kantoff, Philip W., additional, Kathiresan, Sekar, additional, Kathuria, Hasmeena, additional, Kawamoto, Kensaku, additional, Keyser, Filip De, additional, Khalid, Asif, additional, Khoury, Muin, additional, Kingsmore, Stephen F., additional, Kittleson, Michelle M., additional, Koshy, Beena T., additional, Krishnan, Ranga, additional, Krouse, Robert S., additional, Kundra, Vikas, additional, Lai-Goldman, Myla, additional, Lakhani, Vipul, additional, Langer, Robert, additional, Lawler, Sean E., additional, Lee, Inyoul, additional, Lee, Charles, additional, Lee, Arthur S., additional, Leong, Stanely, additional, Lesche, Ralf, additional, Levy, Samuel, additional, Liu, Edison T., additional, Lobach, David F., additional, Lorens, James B., additional, Lusis, Aldons J., additional, Lyerly, H. Kim, additional, Madamanchi, Nageswara R., additional, Martinez, J. Alfredo, additional, Masignani, Vega, additional, McGrath, Kevin, additional, McHutchison, John, additional, Middleton, Frank, additional, Mielants, Herman, additional, Muehlbauer, Michael J., additional, Müller-Ladner, Ulf, additional, Nelson, Mark A., additional, Neri, Monica, additional, Netea, Mihai, additional, Newby, L. Kristin, additional, Newgard, Christopher B., additional, Ng, Maggie, additional, Noble, Paul W., additional, Ntziachristos, Vasilis, additional, Nussbaum, Robert L., additional, O'Donoghue, Meghan B., additional, Odunsi, Kunle, additional, Olden, Kenneth, additional, Ommen, Steve R., additional, Ordovas, Jose M., additional, Patarca, Roberto, additional, Patel, Jeetendra, additional, Patel, K., additional, Pato, Carlos N., additional, Pato, Michele T., additional, Pejovic, Tanja, additional, Perin, Noah C., additional, Pham, Michael, additional, Plenge, Robert M., additional, Plum, Achim, additional, Podgoreanu, Mihai V., additional, Pollack, Jonathan R., additional, Pollex, Rebecca L., additional, Price, Nathan D., additional, Quertermous, Thomas, additional, Quintana, Francisco J., additional, Raby, Benjamin A., additional, Rader, Daniel J., additional, Ramaswamy, Sridhar, additional, Rammensee, Hans-Georg, additional, Ramsey, Scott D., additional, Rappuoli, Rino, additional, Rifai, Nader, additional, Rimsza, Lisa, additional, Rogers, Yu-Hui, additional, Roses, Allen D., additional, Ross, Jeffrey S., additional, Roubenoff, Ronenn, additional, Runge, Marschall S., additional, Scheuner, Maren T., additional, Schuster, Matthias, additional, Schwartz, David A., additional, Schwinn, Debra A., additional, Seng, Chia Kee, additional, Shackel, Nicholas A., additional, Shannon, M. Frances, additional, Sherry, A. Dean, additional, Shi, Jiaqi, additional, Shianna, Kevin, additional, Shnayder, Yelizaveta, additional, Singleton, Andrew B., additional, Slavin, T.P., additional, Smith, Desmond J., additional, Snoeckx, Rikkert L., additional, Snyderman, Ralph, additional, Spira, Avrum, additional, Spraggs, Colin F., additional, Stevens, Robert D., additional, Stewart, Nicolas A., additional, Stewart, Alison, additional, Stewart, F., additional, Strausberg, Robert L., additional, Szyf, Moshe, additional, Tan, Weihong, additional, Tepper, Robert I., additional, Tettelin, Hervé, additional, Thomas, Giovana R., additional, Thompson, John D., additional, Thongboonkerd, Visith, additional, Topol, Eric J., additional, Towbin, Jeffrey A., additional, Bodegraven, Ad A. van, additional, Van Den Bogaert, Kris, additional, Van den Bosch, Filip, additional, Vatta, Matte, additional, Veenstra, Timothy D., additional, Veenstra, David L., additional, Vendrov, Aleksandr E., additional, Verfaillie, Catherine M., additional, Walley, Nicole M., additional, Wang, Ling, additional, Weale, Mike, additional, Weinblatt, Michael E., additional, Weiner, Howard L., additional, Weiss, Scott T., additional, Weissleder, Ralph, additional, Wells, Samuel A., additional, Wenner, Brett R., additional, Wiechers, Ilse R., additional, Wiesner, Georgia L., additional, Wiggs, Janey L., additional, Wijmenga, Cisca, additional, Willard, Huntington F., additional, Wilson, James M., additional, Wivel, Nelson A., additional, Wohlgemuth, Jay, additional, Woodcock, Janet, additional, Woods, Christopher W., additional, Woon, Paula W., additional, Yagil, Chana, additional, Yagil, Yoram, additional, Yamamoto, Tadashi, additional, Yao, Gang, additional, Yee, Andrew J., additional, Yoo, Hyuntae, additional, You, Y. Nancy, additional, Yu, Li-Rong, additional, Zagury, Jean-François, additional, Zimmern, Ron, additional, and Züchner, Stephan, additional

Published
2009
Full Text
View/download PDF

44. The Transmembrane Protein CD37 Is Not a Promising Therapeutic Target in Acute Myeloid Leukaemia

Author

Steinsland, Tara Helen Dowling Dowling, primary, Gullaksen, Stein-Erik, additional, Bredholt, Geir, additional, Leitch, Calum, additional, Safont, Mireia Mayoral, additional, Bruserud, Øystein, additional, Popa, Mihaela, additional, Maaland, Astri, additional, Heyerdahl, Helen, additional, Dahle, Jostein, additional, Gjertsen, Bjorn T., additional, and Mccormack, Emmet, additional

Published
2020
Full Text
View/download PDF

45. The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408)

Author

Loges, Sonja, primary, Heuser, Michael, additional, Chromik, Jörg, additional, Vigil, Carlos Enrique, additional, Paschka, Peter, additional, Re, Francesca, additional, Di Renzo, Nicola, additional, Lemoli, Roberto M., additional, Mattei, Daniele Giovanni, additional, Ben-Batalla, Isabel, additional, Hellesoy, Monica, additional, Lorens, Katherine, additional, Birkett, Joseph, additional, McPherson, Stuart, additional, Nautiyal, Jaya, additional, Micklem, David, additional, Gabra, Hani, additional, Lorens, James B., additional, Fiedler, Walter, additional, Alvarado, Yesid, additional, and Gjertsen, Bjorn T., additional

Published
2020
Full Text
View/download PDF

46. The added value of multi‐state modelling in a randomized controlled trial: The HOVON 102 study re‐analyzed.

Author

Bakunina, Katerina, Putter, Hein, Versluis, Jurjen, Koster, Eva A. S., van der Holt, Bronno, Manz, Markus G., Breems, Dimitri A., Gjertsen, Bjorn T., Cloos, Jacqueline, Valk, Peter J. M., Passweg, Jakob, Pabst, Thomas, Ossenkoppele, Gert J., Löwenberg, Bob, Cornelissen, Jan J., and de Wreede, Liesbeth C.

Subjects
RANDOMIZED controlled trials, HEMATOPOIETIC stem cell transplantation, STEM cell transplantation, ACUTE myeloid leukemia, STEM cell treatment, INDUCTION chemotherapy, TREATMENT effectiveness
Abstract

Clofarabine is an active antileukemic drug for subgroups of patients with acute myeloid leukemia (AML). Multi‐state models can provide additional insights to supplement the original intention‐to‐treat analysis of randomized controlled trials (RCT). We re‐analyzed the HOVON102/SAKK30/09 phase III RCT for newly diagnosed AML patients, which randomized between standard induction chemotherapy with or without clofarabine. Using multi‐state models, we evaluated the effects of induction chemotherapy outcomes (complete remission [CR], measurable residual disease [MRD]), and post‐remission therapy with allogeneic stem cell transplantation [alloSCT] on relapse and death. Through the latter a consistent reduction in the hazard of relapse in the clofarabine arm compared to the standard arm was found, which occurred irrespective of MRD status or post‐remission treatment with alloSCT, demonstrating a strong and persistent antileukemic effect of clofarabine. During the time period between achieving CR and possible post‐remission treatment with alloSCT, non‐relapse mortality was higher in patients receiving clofarabine. An overall net benefit of treatment with clofarabine was identified using the composite endpoint current leukemia‐free survival (CLFS). In conclusion, these results enforce and extend the earlier reported beneficial effect of clofarabine in AML and show that multi‐state models further detail the effect of treatment on competing and series of events. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

47. Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Author

Kreitman, Robert J., primary, Dearden, Claire E., additional, Zinzani, Pier Luigi Luigi, additional, Delgado, Julio, additional, Robak, Tadeusz, additional, le Coutre, Philipp D, additional, Gjertsen, Bjorn T., additional, Troussard, Xavier, additional, Roboz, Gail J., additional, Karlin, Lionel, additional, Gladstone, Douglas E, additional, Kuptsova-Clarkson, Nataliya, additional, Liu, Shiyao, additional, Patel, Priti, additional, Wilson, Wyndham, additional, Pastan, Ira, additional, and Giles, Francis J., additional

Published
2019
Full Text
View/download PDF

48. Durable Responses Observed in Elderly AML Patients Unfit for Intensive Chemotherapy with First-in Class Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with LDAC: Phase II Open-Label Study

Author

Loges, Sonja, primary, Heuser, Michael, additional, Chromik, Jörg, additional, Vigil, Carlos Enrique, additional, Paschka, Peter, additional, Re, Francesca, additional, Di Renzo, Nicola, additional, Lemoli, Roberto Massimo, additional, Mattei, Daniele Giovanni, additional, Ben Batalla, Isabel, additional, Hellesoy, Monica, additional, Micklem, David, additional, Holt, Robert J., additional, Lorens, James B., additional, Shoaib, Muhammad, additional, Aly, Hassan, additional, Hanekom, Wouter, additional, Fiedler, Walter, additional, Cortes, Jorge E., additional, and Gjertsen, Bjorn T., additional

Published
2019
Full Text
View/download PDF

49. Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

Author

Gambacorti-Passerini, Carlo, primary, Brümmendorf, Tim H, additional, Gjertsen, Bjorn T., additional, Abboud, Camille, additional, Rosti, Gianantonio, additional, Abruzzese, Elisabetta, additional, Leip, Eric, additional, Viqueira, Andrea, additional, García Gutiérrez, Valentín, additional, Giles, Frank, additional, and Hochhaus, Andreas, additional

Published
2019
Full Text
View/download PDF

50. Abstract 458: Precision systems medicine in acute myeloid leukemia: real-time translation of tailored therapeutic opportunities arising from ex-vivo drug sensitivity testing and molecular profiling

Author

Malani, Disha, primary, Kumar, Ashwni, additional, Yadav, Bhagwan, additional, Kontro, Mika, additional, Potdar, Swapnil, additional, Bruck, Oscar, additional, Kytölä, Säri, additional, Saarela, Jani, additional, Eldfors, Samuli, additional, Karjalainen, Riikka, additional, Majumder, Muntasir M., additional, Västrik, Imre, additional, Ellonen, Pekka, additional, Kankainen, Matti, additional, Suvela, Minna, additional, Knappila, Siv, additional, Parson, Alun, additional, Palva, Aino, additional, Mattila, Pirkko, additional, Kulesskiy, Evgeny, additional, Turunen, Laura, additional, Laamanen, Karoliina, additional, Lehtinen, Elina, additional, Nurmi, Maria, additional, Suomi, Katja, additional, Muruimägi, Astrid, additional, Gjertsen, Bjorn T., additional, Mustjoki, Satu, additional, Anders, Simon, additional, Wolf, Maija, additional, Aittokallio, Tero, additional, Wennerberg, Krister, additional, Heckman, Caroline, additional, Porkka, Kimmo, additional, and Kallioniemi, Olli, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results